Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Antidepressant Activity Taurine Containing Derivative of 4-Phenylpyrrolidone-2 in a Model of Chronic Unpredictable Mild Stress

Denis A Borozdenko
ORCID logo ,
Darya I. Gonchar
ORCID logo ,
Vlada I. Bogorodova
,
Dmitri V. Tarasenko
,
Eugene P Kramarova
,
Svetlana S. Khovanova
,
Yaroslav V. Golubev
,
Nina M. Kiseleva
,
Tatiana Anatolievna Shmigol
ORCID logo ,
Aiarpi A. Ezdoglian
,
Konstantin A. Sobyanin
ORCID logo ,
Vadim V. Negrebetsky
,
Yuri. I. Baukov
*
Version 1 : Received: 26 October 2023 / Approved: 27 October 2023 / Online: 27 October 2023 (12:53:20 CEST)

A peer-reviewed article of this Preprint also exists.

Borozdenko, D.A.; Gonchar, D.I.; Bogorodova, V.I.; Tarasenko, D.V.; Kramarova, E.P.; Khovanova, S.S.; Golubev, Y.V.; Kiseleva, N.M.; Shmigol, T.A.; Ezdoglian, A.A.; Sobyanin, K.A.; Negrebetsky, V.V.; Baukov, Y.I. The Antidepressant Activity of a Taurine-Containing Derivative of 4-Phenylpyrrolidone-2 in a Model of Chronic Unpredictable Mild Stress. Int. J. Mol. Sci. 2023, 24, 16564. Borozdenko, D.A.; Gonchar, D.I.; Bogorodova, V.I.; Tarasenko, D.V.; Kramarova, E.P.; Khovanova, S.S.; Golubev, Y.V.; Kiseleva, N.M.; Shmigol, T.A.; Ezdoglian, A.A.; Sobyanin, K.A.; Negrebetsky, V.V.; Baukov, Y.I. The Antidepressant Activity of a Taurine-Containing Derivative of 4-Phenylpyrrolidone-2 in a Model of Chronic Unpredictable Mild Stress. Int. J. Mol. Sci. 2023, 24, 16564.

Abstract

This study investigates the therapeutic potential of new compound, potassium 2-[2-(2-oxo-4-phenylpyrrolidin-1-yl) acetamido]ethanesulfonate (Compound I), in depression. Willner's chronic unpredictable mild stress model of depression in 48 male Wistar rats was used a depression model. The rats were randomized into four groups, including an intact group, a Compound I group, a Fluoxetine group, and a control group receiving saline. Behavioral tests, such as the Porsolt forced swim test, hole-board test, elevated plus maze test, and light-dark box, were used to assess the animals' conditions. Our results demonstrated that Compound I effectively reduced the immobilization time of rats in the forced swim test, increased orientation and exploratory behavior, and decreased the latency period of going into the dark compartment compared to the control group. Hippocampal and striatal serotonin concentrations were increased in the Compound I group, and the compound also reduced the level of corticosterone in the blood plasma of rats compared to intact animals. These results suggest that Compound I has a reliable antidepressant activity, comparable to that of the reference antidepressant Fluoxetine.

Keywords

fluoxetine 1; antidepressant activity 2; chronic unpredictable mild stress 3; 4-phenylpyrrolidinone-2 derivative 4; hormones 5

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.